BIRC5 and neoplasm: As survivin requires XPO-1/XPO1-RanGTP for its nuclear exit, inhibiting the activity of this complex could directly address this therapeutic need by increasing the tumor-suppressive nuclear survivin and reducing the antiapoptotic cytoplasmic survivin.